Cytokine Indexes in Pemphigus Vulgaris: Perception of Its Immunpathogenesis and Hopes for Non-Steroidal Treatment

Mohsen Masjedi, Nafiseh Esmaeil, Ali Saffaei, Bahareh Abtahi-Naeini, Mohsen Pourazizi, Shaghayegh Haghjooy Javanmard, Ali Asilian, Mohsen Masjedi, Nafiseh Esmaeil, Ali Saffaei, Bahareh Abtahi-Naeini, Mohsen Pourazizi, Shaghayegh Haghjooy Javanmard, Ali Asilian

Abstract

Pemphigus vulgaris (PV) is a chronic autoimmune blistering disease of the skin, in which loss of adhesion between keratinocytes is caused by autoantibodies. It has been hypothesized that cytokines play an essential role in the pathogenesis of PV. This study aimed to investigate the other immunopathological aspects of PV by determining the serum levels of cytokines in PV patients to find another treatment strategy except corticosteroid therapy. Twenty-three patients with PV and a control group consisting of 24 healthy subjects were studied. Interleukin (IL)-2, IL-4, IL-6, IL10, IL-12, IL-17 and interferon-gamma (IFN-γ) were measured in the sera of patients by the enzyme-linked immunosorbent assay (ELISA) method. The serum levels of IL-2, IL-4, IL-17 and IFN-γ in most patients and controls were undetectable. The serum concentrations of IL-10 in the patients and controls were undetectable, nevertheless, the mean serum levels of this cytokine was 64.375 pg/mL in four patients. The mean serum levels of pro-inflammatory cytokine IL-6 increased significantly in the patients, compared to the controls (169.50 vs. 75.62 pg/mL) (P < 0.05). The same was observed for another pro-inflammatory cytokine, IL-12 (135.33 vs. 86.28 pg/mL) (P < 0.05). Based on the results of this study it can be concluded that the Type 2 T helper cytokine (IL-6) and macrophage-derived cytokine (IL-12) have essential roles in PV pathophysiology. In addition, the potential clinical application of Th1/Th2 type cytokine-based therapy in PV should be considered in next studies.

Keywords: Interferon; Interleukin; Pemphigus vulgaris; Th1 cytokines; Th2 cytokines.

Figures

Figure 1
Figure 1
The serum levels of IL-6 in the patients with pemphigus vulgaris
Figure2
Figure2
The serum levels of IL-12 in the patients with pemphigus vulgaris.

References

    1. Aksu D, Peksari Y, Arica IE, Gurgey E. Assessing the autoantibody levels in relation to disease severity and therapy response in pemphigus patients. Indian J. Dermatol. . 2010;55:342–7.
    1. Satyam A, Khandpur S, Sharma VK, Sharma A. Involvement of T(H)1/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris. Immunol. Invest. . 2009;38:498–509.
    1. Giordano CN, Sinha AA. Cytokine networks in Pemphigus vulgaris: an integrated viewpoint. Autoimmunity . 2012;45:427–39.
    1. Mortazavi H, Esmaili N, Khezri S, Khamesipour A, Vasheghani Farahani I, Daneshpazhooh M, Rezaei N. The effect of conventional immunosuppressive therapy on cytokine serum levels in pemphigus vulgaris patients. Iran J. Allergy Asthma Immunol. . 2014;13:174–83.
    1. Bernink J, Mjosberg J, Spits H. Th1- and Th2-like subsets of innate lymphoid cells. Immunol. Rev. . 2013;252:133–8.
    1. Cope A, Le Friec G, Cardone J, Kemper C. The Th1 life cycle: molecular control of IFN-gamma to IL-10 switching. Trends Immunol. . 2011;32:278–86.
    1. Kosmaczewska A, Swierkot J, Ciszak L, Wiland P. [The role of Th1, Th17, and Treg cells in the pathogenesis of rheumatoid arthritis including anti-inflammatory action of Th1 cytokines] Postepy Hig. Med. Dosw. (Online) 2011;65:397–403.
    1. Singh S, Singh U, Pandey SS. Serum concentration of IL-6, IL-2, TNF-alpha, and IFNgamma in Vitiligo patients. Indian J. Dermatol. . 2012;57:12–4.
    1. Camporeale A, Poli V. IL-6, IL-17 and STAT3: a holy trinity in auto-immunity? Front Biosci (Landmark Ed) 2012;17:2306–26.
    1. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat. Immunol. . 2012;13:722–8.
    1. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr. Opin. Immunol. . 2007;19:281–6.
    1. Raychaudhuri SK, Raychaudhuri SP. Scid mouse model of psoriasis: a unique tool for drug development of autoreactive T-cell and th-17 cell-mediated autoimmune diseases. Indian J. Dermatol. . 2010;55:157–60.
    1. Vaishnani JB, Bosamiya SS. Pemphigus: active or inactive? Indian J. Dermatol. . 2009;54:186–8.
    1. Zakka LR, Shetty SS, Ahmed AR. Rituximab in the treatment of pemphigus vulgaris. Dermatol. Ther. (Heidelb) 2012;2:17.
    1. Grover S. Scoring systems in pemphigus. Indian J. Dermatol. . 2011;56:145–9.
    1. Azizi A, Lawaf S. The management of oral pemphigus vulgaris with systemic corticosteroid and dapsone. J. Dent. Res. Dent. Clin. Dent. Prospects . 2008;2:33–7.
    1. Masjedi M, Asilian A, Shahmoradi Z, Rajabi Dehnavi P, Abtahi Naeini B. Successful treatment of pemphigus vulgaris with the extensive mucocutaneous lesions in an elderly patient. Iran. Red. Crescent. Med. J. . 2014;16:e13967.
    1. Blitstein-Willinger E, Stuttgen G. [Interleukin 2 deficiency in pemphigus vulgaris] Z. Hautkr. . 1986;61:82–5.
    1. Prussick R, Plott RT, Stanley JR. Recurrence of pemphigus vulgaris associated with interleukin 2 therapy. Arch. Dermatol. . 1994;130:890–3.
    1. Masjedi M, Saffaei A, Eskandari N, Abtahi-naeini B, Esmaeili N. Relationship between the serum levels of IL-2 and recurrence of pemphigus vulgaris. Am. J. Exp. Clin. Res. . 2014;1:80.
    1. Caproni M, Giomi B, Cardinali C, Salvatore E, Pestelli E, D›Agata A, Bianchi B, Toto P, Feliciani C, Fabbri P. Further support for a role for Th2-like cytokines in blister formation of pemphigus. Clin. Immunol. . 2001;98:264–71.
    1. Toumi A, Abida O, Ben Ayed M, Masmoudi A, Turki H, Masmoudi H. Cytokine gene polymorphisms in Tunisian endemic pemphigus foliaceus: a possible role of il-4 variants. Hum. Immunol. . 2013;74:658–65.
    1. Steinke JW. Current prospective of anti-IL-4, -IL-9, and -IL-13 therapies in allergic disease. Recent Pat. Inflamm. Allergy Drug Discov. . 2010;4:222–30.
    1. D›Auria L, Bonifati C, Mussi A, D›Agosto G, De Simone C, Giacalone B, Ferraro C, Ameglio F. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur. Cytokine Netw. . 1997;8:383–7.
    1. Bhol KC, Rojas AI, Khan IU, Ahmed AR. Presence of interleukin 10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid. Cytokine . 2000;12:1076–83.
    1. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. . 2012;8:1237–47.
    1. Haddad EA, Senger LK, Takei F. An accessory role for B cells in the IL-12-induced activation of resting mouse NK cells. J. Immunol. . 2009;183:3608–15.
    1. Arakawa M, Dainichi T, Ishii N, Hamada T, Karashima T, Nakama T, Yasumoto S, Tsuruta D, Hashimoto T. Lesional Th17 cells and regulatory T cells in bullous pemphigoid. Exp. Dermatol. . 2011;20:1022–24.
    1. Keskin DB, Stern JN, Fridkis-Hareli M, Razzaque Ahmed A. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy. Cytokine. . 2008;41:315–21.
    1. Lin M-S, Swartz SJ, Lopez A, Ding X, Fernandez-Vina MA, Stastny P, Fairley JA, Diaz LA. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J. Clin. Invest. . 1997;99:31.
    1. Armitage RJ, Macduff B, Spriggs M, Fanslow W. Human B cell proliferation and Ig secretion induced by recombinant CD40 ligand are modulated by soluble cytokines. J. Immunol. . 1993;150:3671–80.
    1. Romagnani S. Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int. Arch. Allergy Immunol. . 1992;98:279–85.
    1. Kwon E, Yamagami J, Nishikawa T, Amagai M. Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission. J. Eur. Acad. Dermatol. Venereol. . 2008;22:1070–75.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit